{{Rsnum
|rsid=9315050
|Gene=ALOX5AP
|Chromosome=13
|position=30761908
|Orientation=plus
|GMAF=0.0978
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ALOX5AP
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 90.8 | 9.2 | 0.0
| HCB | 93.3 | 6.7 | 0.0
| JPT | 97.8 | 2.2 | 0.0
| YRI | 52.4 | 38.1 | 9.5
| ASW | 0.0 | 0.0 | 0.0
| CHB | 93.3 | 6.7 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}

[[rs9315050]], also known as SG13S41, is an [[ALOX5AP]] gene SNP that has been defined as part of a haplotype potentially associated with risk for [[myocardial infarction]] or ischemic [[stroke]]. Details of this haplotype and several related studies are on the [[ALOX5AP]] page.

{{PMID Auto
|PMID=19130089
|Title=Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis.
|OA=1
}}

{{PMID Auto
|PMID=19665766
|Title=Genetics and pharmacogenetics of the leukotriene pathway.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}